Takeda, Xoma expand antibody ties

Xoma will receive a $29 million payment following Takeda's decision to expand the companies' existing antibody collaboration. Xoma will provide Takeda with access to multiple antibody technologies, including a suite of R&D technologies and integrated information and data management systems. In addition to the expansion fee, Xoma could earn milestones and royalties on antibody products, and will be responsible for up to $7.5 million in taxes and other costs related to the partnership. The companies first teamed up in 2006.

"This collaboration expansion is intended to help accelerate Takeda's corporate goal of building a world class, highly competitive antibody product pipeline by augmenting its already significant in-house capabilities located in San Francisco and Osaka," said Shigenori Ohkawa, PhD, General Manager of Pharmaceutical Research Division of Takeda. "With the antibody technologies of Xoma, we will further complement our antibody research activities for the creation of new drugs."

- take a look at the release from Xoma
- here's the Hays Pharma article

Related Articles:
Xoma cuts 144 jobs in restructuring
Xoma and Texas A&M sign deal
Xoma diabetes antibody positive after one dose